madman
Super Moderator
In a program supported by Verity Pharmaceuticals, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego; Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center; and Benjamin H. Lowentritt, MD, FACS, Director of Prostate Cancer Services for United Urology Group discuss androgen deprivation therapy (ADT) as a foundational therapy for prostate cancer. They discuss managing T levels, adherence to T dosing schedules, and redefining castrate-resistant prostate cancer (CRPC).
